News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 644 results
May 2014
-
Media ReleaseNovartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
-
Media ReleaseNovartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analoguesAcromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality(1,2)Phase III data show patients on…
-
Media ReleaseNovartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
April 2014
-
Media ReleaseNovartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list-- Number one ranking acknowledges Novartis Pharmaceuticals Corporation's commitment to and leadership in diversity and inclusion-- Reflects a decade of effort to embed diversity and inclusion into…
-
Media ReleaseNovartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list
March 2014
-
Media ReleaseNovartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2)- Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or…
-
Media ReleaseNovartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media ReleaseNovartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age…
-
Media ReleaseNovartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
January 2014
-
Media ReleaseNovartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safetyPatient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) Patient adherence activities provide important education and support to help patients…
-
Media ReleaseNovartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
Pagination
- ‹ Previous page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- …
- 54
- › Next page